Fused pyrimidines as KRAS inhibitors

The present invention relates to fused pyrimidine compounds of general formula (I) wherein R1, R2, R3, R4, X, Y and Z are as defined herein, processes for preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds, and methods for preparing the compounds. And the use of said compounds as a separate agent or in combination with other active ingredients for the preparation of pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular neoplastic diseases, respectively cancer or immune response disorder conditions or other diseases associated with abnormal KRAS signaling. # imgabs0 # 本发明涉及通式(I)的稠合嘧啶化合物，其中R1、R2、R3、R4、X、Y和Z如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合，以及所述化合物作为单独药剂或与其他活性成分结合用于制备用于治疗或预防疾病，特别是肿瘤性疾病，分别为癌症或免疫反应失调病况或与异常KRAS信号传导相关的其他疾病的药物组合物的用途。#imgabs0#